Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. increased its position in shares of Blueprint Medicines Corporation (NASDAQ:BPMC) by 34.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,220,446 shares of the biotechnology company’s stock after buying an additional 313,181 shares during the period. Vanguard Group Inc.’s holdings in Blueprint Medicines Corporation were worth $48,806,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Teachers Advisors LLC raised its stake in shares of Blueprint Medicines Corporation by 2.7% in the fourth quarter. Teachers Advisors LLC now owns 32,932 shares of the biotechnology company’s stock worth $924,000 after buying an additional 881 shares during the period. Prudential Financial Inc. raised its stake in shares of Blueprint Medicines Corporation by 6.0% in the first quarter. Prudential Financial Inc. now owns 17,304 shares of the biotechnology company’s stock worth $692,000 after buying an additional 984 shares during the period. Legal & General Group Plc raised its stake in shares of Blueprint Medicines Corporation by 31.8% in the first quarter. Legal & General Group Plc now owns 5,884 shares of the biotechnology company’s stock worth $235,000 after buying an additional 1,419 shares during the period. American International Group Inc. raised its stake in shares of Blueprint Medicines Corporation by 28.0% in the first quarter. American International Group Inc. now owns 14,728 shares of the biotechnology company’s stock worth $589,000 after buying an additional 3,221 shares during the period. Finally, Swiss National Bank raised its stake in shares of Blueprint Medicines Corporation by 12.1% in the first quarter. Swiss National Bank now owns 46,300 shares of the biotechnology company’s stock worth $1,852,000 after buying an additional 5,000 shares during the period. 88.67% of the stock is currently owned by hedge funds and other institutional investors.

Blueprint Medicines Corporation (NASDAQ:BPMC) traded up 0.11% during midday trading on Friday, reaching $47.01. 72,989 shares of the company’s stock traded hands. Blueprint Medicines Corporation has a 1-year low of $23.71 and a 1-year high of $56.81. The firm’s 50 day moving average price is $51.95 and its 200-day moving average price is $42.50. The company’s market capitalization is $1.84 billion.

Blueprint Medicines Corporation (NASDAQ:BPMC) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.11. The business had revenue of $5.89 million during the quarter, compared to analyst estimates of $5.96 million. Blueprint Medicines Corporation had a negative net margin of 388.91% and a negative return on equity of 45.58%. The company’s revenue for the quarter was down 16.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.70) earnings per share. Equities analysts expect that Blueprint Medicines Corporation will post ($3.59) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2801385/blueprint-medicines-corporation-nasdaqbpmc-shares-bought-by-vanguard-group-inc.html.

A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Blueprint Medicines Corporation from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Canaccord Genuity set a $56.00 price objective on shares of Blueprint Medicines Corporation and gave the company a “buy” rating in a report on Wednesday, August 2nd. TheStreet lowered shares of Blueprint Medicines Corporation from a “c-” rating to a “d+” rating in a report on Wednesday, May 3rd. Wedbush reissued an “outperform” rating and set a $55.00 price objective on shares of Blueprint Medicines Corporation in a report on Tuesday, June 6th. Finally, Cowen and Company reissued a “buy” rating on shares of Blueprint Medicines Corporation in a report on Tuesday, June 6th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Blueprint Medicines Corporation has an average rating of “Buy” and an average price target of $47.90.

In other Blueprint Medicines Corporation news, Director Daniel Lynch sold 7,500 shares of Blueprint Medicines Corporation stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $55.06, for a total value of $412,950.00. Following the transaction, the director now directly owns 211,842 shares in the company, valued at $11,664,020.52. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Kate Haviland sold 6,357 shares of Blueprint Medicines Corporation stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $50.00, for a total transaction of $317,850.00. Following the completion of the transaction, the insider now owns 6,357 shares in the company, valued at $317,850. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 123,622 shares of company stock worth $6,241,605. 3.40% of the stock is currently owned by company insiders.

Blueprint Medicines Corporation Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corporation (NASDAQ:BPMC).

Institutional Ownership by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.